Please use this identifier to cite or link to this item:
Title: Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
Authors: Hillman, Richard J
Giuliano, Anna R
Palefsky, Joel M
Goldstone, Stephen
Moreira Júnior, Edson Duarte
Vardas, Eftyhia
Aranda, Carlos
Jessen, Heiko
Ferris, Daron G
Coutlee, Francois
Marshall, J. Brooke
Vuocolo, Scott
Haupt, Richard M
Guris, Dalya
Garner, Elizabeth I. O
Affilliation: University of Sydney. STI Research Centre. Sydney, Australia
Risk Assessment, Detection, and Intervention Program, H. Lee Moffitt Cancer Center. Florida, USA / Research Institute,Tampa. Florida, USA
University of California San Francisco. Department of Medicine. San Francisco, California, USA
Mount Sinai School of Medicine. New York, New York, USA
Associação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
University of Stellenbosch. Division of Medical Virology, South Africa / Lancet Laboratories. Johannesburg, South
University Medical Center. National Public Health Institute. Morelos, Mexico
J2 PrivateClinic for Infectious Diseases. Berlin,
Georgia Health Sciences University. Gynecologic Cancer Prevention Center. Augusta, Georgia
Centre de recherche duCHUM, Université de Montréal. Montréal, Quebec,
Merck & Co., Inc. North Wales, Pennsylvania, USA
Merck & Co., Inc. North Wales, Pennsylvania, USA
Merck & Co., Inc. North Wales, Pennsylvania, USA
Merck & Co., Inc. North Wales, Pennsylvania, USA
Merck & Co., Inc. North Wales, Pennsylvania, USA
Abstract: Human papillomavirus (HPV) infection can lead to significant disease in males, including anogenital warts, intraepithelial neoplasias, and several types of oral and anogenital cancers. The quadrivalent HPV (type 6/11/16/18) L1 virus-like particle (VLP) vaccine (qHPV vaccine; Gardasil) has recently been demonstrated to prevent persistent infection and associated disease related to vaccine HPV types in males. We report the overall immunogenicity results from a trial of the quadrivalent HPV vaccine in males. Overall, 3,463 heterosexual men and 602 men who had sex with men were enrolled into a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study. Serum samples were collected prior to vaccination at day 1 and at months 7, 24, and 36 postvaccination. Immunogenicity was evaluated with a multiplex, competitive Luminex immunoassay. Almost all subjects (97.4 to 99.2%) seroconverted for vaccine HPV types by month 7. At month 36, 88.9%, 94.0%, 97.9%, and 57.0% of subjects were still seropositive for HPV-6, -11, -16, and -18, respectively. For all vaccine HPV types, black subjects had significantly higher antibody titers at month 7 than did both Caucasian and Asian subjects. An anamnestic antibody response was seen in men seropositive before vaccination. The vaccine was highly immunogenic in males 16 to 23 years of age; responses were comparable to those observed in women. Furthermore, the immune responses were consistent with the established efficacy of the vaccine in the prevention of incident and persistent HPV infection, anogenital warts, and anal intraepithelial neoplasia.
DeCS: Carcinoma in Situ/prevenção & controle
Condiloma Acuminado/prevenção & controle
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus/imunologia
Anticorpos Antivirais/sangue
Carcinoma in Situ/virologia
Condiloma Acuminado/imunologia
Método Duplo-Cego
Papillomavirus Humano 11/imunologia
Papillomavirus Humano 16/imunologia
Infecções por Papillomavirus/imunologia
Adulto Jovem
Issue Date: 2012
Publisher: American Society for Microbiology
Citation: HILLMAN, R. J. et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clinical and Vaccine Immunology, v. 19, n. 2, p. 261-267, 2012.
DOI: 10.1128/CVI.05208-11
ISSN: 1556-679X
Copyright: open access
Appears in Collections:BA - IGM - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Hillman RJ Immunogenicity....pdf326.05 kBAdobe PDFView/Open

FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.